Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
March 5, 2012

Meda MP29-02 shows efficacy in clinical studies

Meda's MP29-02 (Dymista) was found to be well tolerated and effective in three clinical trials conducted in patients with chronic allergic or non-allergic rhinitis.

Meda’s MP29-02 (Dymista) was found to be well tolerated and effective in three clinical trials conducted in patients with chronic allergic or non-allergic rhinitis.

MP29-02 is an intranasal formulation of azelastine hydrochloride and fluticasone propionate, and is under review by the US Food and Drug Administration (FDA) for the treatment of seasonal allergic rhinitis (SAR).

In the randomised open-label active-controlled parallel-group first study, 612 patients were treated with either MP29-02 one spray per nostril twice daily or fluticasone propionate two sprays per nostril once daily.

During the one-year period, the study evaluated safety and tolerability, and also assessed efficacy by measuring the 12-hour reflective total nasal symptom score (rTNSS) scored once daily.

The first study demonstrated that continuous treatment with MP29-02 was well tolerated and showed greater relief from nasal symptoms than fluticasone-treated patients over the one-year study period.

Lead author of the first study William Berger said: "These data show support for the safety and efficacy of this novel nasal spray formulation, especially for patients who have persistent symptoms of seasonal allergic rhinitis that may require longer-term treatment."

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The randomised double-blind placebo and active controlled two week pivotal trials, MP4002 and MP4004, conducted in more than 1600 patients with moderate-to-severe SAR evaluated MP29-02 for the treatment of ocular symptoms associated with SAR, a key secondary endpoint in the MP29-02 clinical development programme.

The primary endpoint of the trials was change from baseline in the 12-hour reflective total nasal symptom score (rTNSS), and the secondary endpoint was the 12-hour reflective total ocular symptom score (rTOSS), including itchy eyes, watery eyes, and eye redness.

In the second and third studies, patients with SAR demonstrated considerable relief from nasal symptoms and also improved TOSS compared to placebo over a two-week study period.

Meda CEO Anders Lönner said: "These data provide additional important evidence that Dymista can offer significant benefits to patients and may play a critical role in the future treatment of patients with SAR."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU